RBC Capital Maintains Outperform on Boston Scientific, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh maintains an Outperform rating on Boston Scientific (NYSE:BSX) and raises the price target from $67 to $70.
February 01, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Shagun Singh maintains an Outperform rating on Boston Scientific and raises the price target from $67 to $70.
The increase in price target by RBC Capital indicates a positive outlook on Boston Scientific's stock, suggesting potential upside. This is likely to be viewed positively by investors, potentially driving short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100